Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement
Acta Biomaterialia · 2023
DOI: 10.1016/j.actbio.2023.08.036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2023. Verfasst von Dipasha Sinha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Bioprosthesis, Heart Defects, Congenital, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIBIB NIH HHS, Seattle Translational Tumor Research.
Abstract (Originalsprache)
Congenital heart diseases (CHD) are one of the most frequently diagnosed congenital disorders, affecting approximately 40,000 live births annually in the United States. Out of the new patients diagnosed with CHD yearly, an estimated 2,500 patients require a substitute, non-native conduit artery to replace structures congenitally absent or hypoplastic. Devices used for conduit replacement encounter limitations exhibiting varying degrees of stiffness, calcification, susceptibility to infection, thrombosis, and a lack of implant growth capacity. Here, we report the functionality of pentagalloyl glucose (PGG) stabilized decellularized valved bovine jugular vein conduit (PGG-DBJVC). The PGG-DBJVC tissues demonstrated mechanical properties comparable to native and glutaraldehyde fixed tissues, while exhibiting resistance to both collagenase and elastase enzymatic degradation. Subcutaneous implantation of tissues established their biocompatibility and resistance to calcification, while implantation in sheep in the pulmonary position demonstrated adequate implant functionality, and repopulation of host cells, without excessive inflammation. In conclusion, this PGG-DBJVC device could be a favorable replacement option for pediatric patients, reducing the need for reoperations required with current devices. STATEMENT OF SIGNIFICANCE: Congenital Heart Disease (CHD) is a common congenital disorder affecting many newborns in the United States each year. The use of substitute conduit arteries is necessary for some patients with CHD who have missing or underdeveloped structures. Current conduit replacement devices have limitations, including stiffness, susceptibility to infection and thrombosis, and lack of implant growth capacity. Pentagalloyl glucose-stabilized bovine jugular vein valved tissue (PGG-DBJVC) offers a promising solution as it is resistant to calcification, and biocompatible. When implanted in rats and as pulmonary conduit replacement in sheep, the PGG-DBJVC demonstrated cellular infiltration without excessive inflammation, which could lead to remodeling and integration with host tissue and eliminate the need for replacement as the child grows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA.
- Department of Cardiac Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115, USA.
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA. Electronic address: narenv@clemson.edu.
Förderung
- NHLBI NIH HHS
- NIBIB NIH HHS
- Seattle Translational Tumor Research
- National Institutes of Health
Zitieren
APA
Sinha, D., Nagy-Mehesz, A., Simionescu, D., Mayer, J. E., & Vyavahare, N. (2023). Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2023.08.036
Vancouver
Sinha D, Nagy-Mehesz A, Simionescu D, Mayer JE, Vyavahare N. Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement. Acta Biomaterialia. 2023. doi:10.1016/j.actbio.2023.08.036
BibTeX
@article{Sinha2023,
author = {Sinha, Dipasha and Nagy-Mehesz, Agnes and Simionescu, Dan and Mayer, John E and Vyavahare, Naren},
title = {Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement},
journal = {Acta Biomaterialia},
year = {2023},
doi = {10.1016/j.actbio.2023.08.036}
}
EUVIMED